Juvenile Diabetes Research Foundation

Juvenile Diabetes Research Foundation
Name	Juvenile Diabetes Research Foundation
Founded	0 1970
Founders	Lee Ducat, Carol Lurie
Location	New York City, New York, United States
Key people	Aaron J. Kowalski (CEO)
Focus	Type 1 diabetes research, advocacy, and support
Website	https://www.jdrf.org

Juvenile Diabetes Research Foundation is a leading global organization focused on funding research to cure, prevent, and treat type 1 diabetes and its complications. Founded in 1970 by parents of children with the condition, it has grown into one of the world's most influential health charities, driving significant scientific advancements through strategic research funding and powerful advocacy. The organization operates internationally, collaborating with researchers, policymakers, and pharmaceutical companies to accelerate progress toward its mission.

History and founding

The organization was established in Philadelphia in 1970 by Lee Ducat and Carol Lurie, mothers whose sons were diagnosed with type 1 diabetes. Frustrated by the limited research and treatment options available at the time, they mobilized other families, forming the first chapter to raise funds specifically for diabetes research. This grassroots effort quickly gained momentum, attracting support from prominent figures in medicine and philanthropy. The early success in fundraising enabled the fledgling organization to award its first research grants to institutions like the University of Pennsylvania and Joslin Diabetes Center, setting a precedent for its focused, donor-driven approach to science.

Mission and objectives

The core mission is to accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes and its complications. Its primary objectives are to fund innovative research across the spectrum of the disease, from beta cell restoration to advanced glucose management technologies. The organization also aims to advocate for increased public and private research funding, notably through agencies like the National Institutes of Health and the Special Diabetes Program. A further key objective is to provide support and resources for the global type 1 diabetes community, ensuring patients and families have access to the latest information and care.

Research focus and initiatives

Research strategy is directed toward several key pillars, including restoring beta cell function, developing advanced glucose monitoring and automated insulin delivery systems, and preventing the disease. Major initiatives have included funding pivotal artificial pancreas research, leading to technologies like the MiniMed 670G system from Medtronic. The organization also champions research into immunotherapy and stem cell therapies, collaborating with entities like ViaCyte and the Harvard Stem Cell Institute. Its Clinical Trials Network facilitates rapid testing of new therapies across centers like the University of California, San Francisco and Yale University.

Fundraising and advocacy

Fundraising efforts are vast and include signature events like the Walk to Cure Diabetes and the Promise Ball gala, engaging communities across North America and internationally. The organization’s advocacy arm works diligently to influence policy, successfully campaigning for continued funding of the Special Diabetes Program through the United States Congress. It also partners with corporate entities such as Google and Walmart for campaign support. These efforts secure hundreds of millions of dollars annually, which are directly allocated to research programs and scientific partnerships worldwide.

Organizational structure and leadership

Headquartered in New York City, the organization operates through a network of chapters across all 50 U.S. states and in countries like Australia, Canada, and the United Kingdom. Governance is provided by a Board of Directors composed of business leaders, scientists, and community advocates. The scientific direction is guided by a Scientific Review Committee comprised of experts from institutions such as the Stanford University School of Medicine and the Jackson Laboratory. Leadership has included notable figures like Mary Tyler Moore, who served as International Chairman, and current CEO Aaron J. Kowalski, a former researcher at the National Institutes of Health.

Impact and recognition

The organization’s impact is evidenced by its role in co-funding the development of continuous glucose monitors with companies like Dexcom and supporting the research underpinning Teplizumab, a drug delaying the onset of type 1 diabetes. It has been recognized with high ratings from charity evaluators like Charity Navigator for its financial efficiency. The organization’s advocacy has been instrumental in shaping diabetes policy within the Food and Drug Administration and the Centers for Medicare & Medicaid Services. Its funded research has contributed to thousands of scientific publications in journals like The Lancet and Diabetes.

Category:Medical research organizations Category:Diabetes organizations Category:Organizations based in New York City Category:Organizations established in 1970